Concentra Biosciences, LLC has entered into a definitive agreement to acquire Allakos Inc. (Nasdaq: ALLK), a biotechnology company specializing in antibodies for allergic, inflammatory, and proliferative diseases. The all-cash transaction values Allakos at $0.33 per share, as announced by the San Carlos, California-based company on April 2, 2025.
The acquisition comes after unanimous approval from Allakos' Board of Directors, which determined the deal to be in the best interests of all shareholders following a recommendation from the company's Transaction Committee.
Transaction Details and Timeline
Under the terms of the merger agreement, a wholly owned subsidiary of Concentra will commence a tender offer by April 15, 2025, to acquire all outstanding shares of Allakos common stock. The transaction is expected to close in May 2025, subject to customary closing conditions.
Key conditions for closing include the tender of shares representing at least a majority of Allakos' total outstanding shares and the availability of at least $35.5 million in cash at closing, net of transaction costs, wind-down costs, and other liabilities.
Company officers, directors, and their affiliates—who collectively hold approximately 8.07% of Allakos common stock—have already signed support agreements committing to tender their shares and support the merger.
Strategic Implications for Immunomodulatory Research
Allakos has built its research portfolio around therapeutics targeting immunomodulatory receptors present on immune effector cells. These cells play crucial roles in allergic, inflammatory, and proliferative diseases, representing significant unmet medical needs across multiple therapeutic areas.
The acquisition by Concentra Biosciences suggests a strategic consolidation in this specialized research space, potentially allowing for continued development of Allakos' therapeutic pipeline under new ownership.
Financial and Legal Advisors
Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Allakos throughout the transaction process, while Gibson, Dunn & Crutcher LLP is acting as legal counsel to Concentra Biosciences.
Market Context
This acquisition comes at a time when biotech valuations have faced significant pressure, with many clinical-stage companies trading below cash value. The transaction structure—with specific cash requirements at closing—highlights the importance of financial stability in current biotech M&A activity.
For investors and industry observers, the deal represents another example of consolidation in the biotechnology sector, where companies with specialized therapeutic approaches are being acquired by larger entities with the resources to advance clinical development programs.
Adam Tomasi, President of Allakos, and Alex Schwartz, VP of Strategic Finance and Investor Relations, will continue to manage investor relations through the closing period as the companies work toward finalizing the transaction in the coming weeks.
